Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/093671GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS
WO 05.05.2022
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/US2021/056413 Applicant PARTNER THERAPEUTICS, INC. Inventor FELDHAUS, Michael
The present invention is based on the discovery that amino acid substitutions in the sequence of sargramostim yield a product with simplified manufacturability.
2.3196431GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS
CA 05.05.2022
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No 3196431 Applicant PARTNER THERAPEUTICS, INC. Inventor FELDHAUS, MICHAEL
The present invention is based on the discovery that amino acid substitutions in the sequence of sargramostim yield a product with simplified manufacturability.
3.WO/2021/216738COMPOSITIONS AND METHODS OF GENERATING AN IMMUNE RESPONSE
WO 28.10.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/US2021/028436 Applicant INTIMA BIOSCIENCE, INC. Inventor HENLEY, Thomas
Provided herein are compositions and methods for use in generating an immune response against a target peptide antigen. Also included, are methods for stabilizing, treating, and eliminating various diseases and conditions associated with target peptide expression.
4.WO/2022/224203ANTIBODIES THAT BIND SARS-COV-2 SPIKE PROTEIN
WO 27.10.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IB2022/053756 Applicant NATIONAL RESEARCH COUNCIL OF CANADA Inventor TANHA, Jamshid
Described herein are antibodies that specifically recognize the SARS-CoV-2 spike (S) polypeptide,compositions comprising said antibodies, uses thereof, and methods employing said antibodies. Eachantibody specifically recognizes the S1-RBD domain, S1-NTD domain, or S2 subunit of the SARS-CoV-2 spike polypeptide. Some antibodies are cross-reactive with variants of SARS-CoV-2 and othercoronavirus spike polypeptides, such as SARS-CoV S, pangolin CoV S, bat SARS-like CoV S, andcivet SARS-CoV S.
5.WO/2023/201304COMPOSITIONS FOR PREVENTING OR TREATING CORONAVIRUS INFECTIONS
WO 19.10.2023
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2023/065732 Applicant INVISISHIELD TECHNOLOGIES LTD. Inventor LIU, Cheng
The present application relates to compositions for preventing or treating infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety comprising an extracellular binding domain (EBD) of an angiotensin-converting enzyme 2 (ACE2) protein or a fragment thereof that specifically binds to an S protein, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating a viral infection in an individual, such as a coronavirus infection.
6.WO/2021/202929RAPID MULTIPLEXED SEROLOGICAL TEST
WO 07.10.2021
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No PCT/US2021/025456 Applicant GENALYTE, INC. Inventor GUNN, Lawrence, Cary, III
Disclosed herein are methods of performing multiplexed serological immunoassays to detect multiple antigens in parallel to determine if a patient has an infection or an immune disorder. Use of multiple antigens in parallel increases specificity and/or sensitivity towards assaying the infection or immune disorder. The infection may be a viral infection such as a SARS-CoV-2 viral infection, a variant of a SARS-CoV-2 viral infection, or a non-SARS-CoV-2 coronavirus infection. Also disclosed herein are methods of performing the multiplexed serological immunoassays on an optical ring resonator substrate. Also disclosed herein are methods of detecting antibodies specific for an antigen that belong to more than one immunoglobulin type.
7.WO/2021/217178CALIBRATION AND QUALITY CONTROL REAGENTS FOR USE WITH IMMUNOASSAYS FOR ANTIBODIES
WO 28.10.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2021/070436 Applicant SIEMENS HEALTHCARE DIAGNOSTICS INC. Inventor BAHAR, Izak
Calibration and/or quality control reagents are disclosed for use in serology immunoassays for antibodies to a microorganism. In the reagents, antibodies specific to an antigen of the microorganism are complexed with anti-human Ig antibody to form a complex. Kits and microfluidics devices containing the reagents are also disclosed, along with methods of producing and using the reagents.
8.WO/2021/217179COMPOSITIONS, KITS, AND METHODS FOR ANTI-MICROBIAL SEROLOGY ASSAYS USING ANTI-HUMAN IMMUNOGLOBULIN ANTIBODY
WO 28.10.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/070437 Applicant SIEMENS HEALTHCARE DIAGNOSTICS INC. Inventor WEI, Tie
Reagents, kits, and microfluidics devices are disclosed for detecting the presence and/or concentration of antibodies directed to microorganisms in human biological samples. Also disclosed are methods of production and use of the reagents, kits, and microfluidics devices. Anti-human immunoglobulin antibodies are utilized to enhance the signal produced by the assay.
9.WO/2024/036184A HUMAN VH-BASED SCAFFOLD FOR THE PRODUCTION OF SINGLE DOMAIN ANTIBODIES AND THEIR USE
WO 15.02.2024
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/US2023/071893 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE Inventor JARDINE, Joseph
Provided herein are a human VH-based scaffold for the production of single domain antibodies and their use.
10.0930316Oral product for the prevention and treatment of infectious gastroenteritides in calves
EP 21.07.1999
Int.Class A61K 39/108
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
108Escherichia; Klebsiella
Appl.No 98310267 Applicant MEDIPHARM CZ S R O Inventor MICAN PETR
Oral product for the prevention and therapy of infectious gastroenteritis in calves that contents of antibodies to bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli prepared from colostrum of immunized cows and/or egg yolks of immunized hens. It contents also a stabilized live culture of lactacidogenic bacteria. Method of production of antibodies to bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli by immunization of cows and/or hens with antigens of bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli, collection of colostrum from the immunized cows and/or egg yolks from the immunized hens and processing of these semi-products into the administration form, for instance by drying.